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Background: Component resolution recently identified distinct sensitization profiles in honey bee venom (HBV) allergy, some of which were dominated by specific IgE to Api m 3 and/or Api m 10, which have been reported to be underrepresented in therapeutic HBV preparations. Objective: We performed a retrospective analysis of component-resolved sensitization profiles in HBV-allergic patients and association with treatment outcome. Methods: HBV-allergic patients who had undergone controlled honey bee sting challenge after at least 6 months of HBV immunotherapy (n 5 115) were included and classified as responder (n 5 79) or treatment failure (n 5 36) on the basis of absence or presence of systemic allergic reactions upon sting challenge. IgE reactivity to a panel of HBV allergens was analyzed in sera obtained before immunotherapy and before sting challenge. Results: No differences were observed between responders and nonresponders regarding levels of IgE sensitization to Api m 1, Api m 2, Api m 3, and Api m 5. In contrast, Api m 10 specific IgE was moderately but significantly increased in nonresponders. Predominant Api m 10 sensitization (>50% of specific IgE to HBV) was the best discriminator (specificity, 95%; sensitivity, 25%) with an odds ratio of 8.444 (2.127-33.53; P 5 .0013) for treatment failure. Some but not all therapeutic HBV preparations displayed a lack of Api m 10, whereas Api m 1 and Api m 3 immunoreactivity was comparable to that of crude HBV. In line with this, significant Api m 10 sIgG 4 induction was observed only in those patients who were treated with HBV in which Api m 10 was detectable. Key words: Apis mellifera, Hymenoptera venom allergy, HBV allergy, recombinant allergen, allergen-specific immunotherapy, treatment failure Systemic allergic reaction to Hymenoptera stings affects 0.3% to 3.5% of the adult population. 1, 2 Venom immunotherapy (VIT) protects allergic patients from systemic reactions to subsequent stings. 2, 3 The effectiveness of VIT depends on a number of variables such as treatment duration, venom dose during maintenance therapy, and type of venom (honey bee [HB] vs vespid) used for immunotherapy. [4] [5] [6] Treatment failure is more frequent in HB VIT than in vespid VIT, ranging from 11% to 23% as compared with 0% to 9%. [4] [5] [6] [7] A recent retrospective study on the outcome of more than 1600 sting challenges calculated an odds ratio (OR) of more than 5 for treatment failure in honey bee venom (HBV) allergy as compared with VIT in vespid venom allergy. 6 This increased risk of treatment failure in HBV allergy has been suggested to be associated with differences in venom composition, venom dose during natural exposure conditions, and differences in sensitization profiles. 4, 7, 8 Advances in proteomics and molecular biology have allowed a detailed characterization of the protein composition of HBV. The best-characterized HBV allergens are phospholipase A2 (Api m 1), hyaluronidase (Api m 2), and the basic peptide melittin (Api m 4). 9, 10 Additional HBV allergens of lower abundance have been cloned and characterized such as acid phosphatase (Api m 3), 11 dipeptidylpeptidase IV (Api m 5), 12 icarapin (Api m 10), 13, 14 and others as recently reviewed. 15 Analysis of different venom preparations have shown that Api m 3 and Api m 10, while present in the crude HBV, are absent or underrepresented in preparations used for HBV immunotherapy. 13 These findings were supported by subsequent observations that in patients with dominant sensitization to Api m 10, IgE reactivity to HBV could be inhibited by crude HBV preparations but not by therapeutic HBV preparations. 8 In addition, HBV-allergic patients who had undergone VIT displayed a strong induction of sIgG 4 to Api m 1, Api m 2, and Api m 4, whereas no or little induction of sIgG 4 to Api m 3 and Api m 10 could be detected. 8 On the basis of these 3 lines of evidence, we hypothesized that the absence or underrepresentation of Api m 3 and Api m 10 in therapeutic HBV preparations may have an impact on the treatment outcome of VIT and that distinct sensitization profiles, for example, with predominant IgE reactivity to Api m 3 and/or Api m 10, may represent a potential risk factor for treatment failure of VIT in HBV allergy. To address this issue, we here retrospectively analyzed the molecular sensitization profiles in HBVallergic patients who had undergone controlled HB sting challenge after at least 6 months of HBV.
METHODS Patients
Sera from HBV-allergic patients who had undergone controlled HB sting challenge after at least 6 months of HBV immunotherapy at a maintenance dose of 100 mg BV were included in the study (n 5 115) and classified as responder, that is, protected (n 5 79), or treatment failure, that is, not protected (n 5 36), on the basis of the absence or presence of systemic allergic reactions upon sting challenge. The study was performed retrospectively using banked sera from patients initiated on HB VIT during August 1993 and November 2013 in 6 different clinical allergy centers that routinely perform sting challenge testing, and was approved by respective local ethic committees. Diagnosis of HBV allergy was based on a combination of patient's history of a systemic sting reaction, a positive skin test result, and positive specific IgE (sIgE) to HBV (> _0.35 kU A /L; ImmunoCAP i1), as recently described. 8 All centers were asked to include patients at a 2:1 ratio of responders versus nonresponders for which they could provide serum samples obtained before initiation of VIT and during VIT before sting challenge. For each patient, the following data were obtained from the records: history and grade of anaphylactic HB sting reaction (according to Ring & Messmer), 16 skin test results, serology and tryptase levels at the time of initial diagnosis, date and treatment protocol of VIT, concomitant yellow jacket VIT, type, maintenance dose, and duration of HB VIT before sting challenge, systemic reactions during HB VIT, symptoms of systemic allergic reactions, and antihypertensive medication during sting challenge.
Statistical analysis
Statistical analysis was performed using the nonparametric Mann-Whitney U test for unpaired data and the Wilcoxon signed-rank test for paired data. ORs were calculated from contingency tables using the Fisher exact test on Graph Pad Prism 6 software. P values of less than .05 were regarded as significant. Calculation of diagnostic accuracy measures was performed using SPSS (IBM SPSS Statistics, Version 22.0.0.0, Ehningen, Germany) and the open statistical software environment R. 17 These were sensitivity, specificity, positive likelihood ratio (PLR) 5 sensitivity/(1 2 specificity), negative likelihood ratio (NLR) 5 (1 2 sensitivity)/specificity, receiver operating characteristic (ROC) curve, and area under the ROC curve (AUC).
For additional information on allergens, sIgE and sIgG 4 measurements, antisera, and immunoblot analysis, please see the Methods section in the Online Repository at www.jacionline.org. 8 Demographic and clinical data (age, sex, degree of anaphylaxis during index sting, treatment duration before sting challenge, and previously suggested risk factors for treatment failure) are summarized in Table I .
RESULTS

IgE
The comparison of responders (n 5 79) and nonresponders (n 5 36) before the initiation of VIT demonstrated no significant difference in level of sIgE to Api m 1, Api m 2, Api m 3, and Api m 5. In contrast, sIgE to HBVand to Api m 10 was moderately but significantly increased in nonresponders (Fig 1) . We next compared the percentage of sIgE directed against individual allergens in relation to sIgE directed against the entire HBV (i1) in both patient groups. Although no significant differences were observed for Api m 1, Api m 2, and Api m 5, nonresponders displayed significantly increased percentage of sIgE to Api m 10 and a slightly reduced percentage of sIgE to Api m 3 in relation to sIgE to the entire HBV (Fig 2) . Similarly, nonresponders displayed moderately but significantly increased percentage of sIgE to Api m 10 in relation to total IgE (see Fig E2 in this article's Online Repository at www.jacionline.org).
On analyzing the ROCs of Api m 10 sIgE (AUC, 0.687; P 5 .001) (Fig 3, A) , the best discrimination between responders and nonresponders (ie, the highest Youden's index) was observed at values of 1.82 kU A /L with a specificity of 70.9% (95% CI, 56.0% to 85.7%), a sensitivity of 69.4% (95% CI, 54.4% to 84.5%), a PLR of 2.39, and an NLR of 0.43. The cutoff of more than 0.35 kU A /L provided a specificity of 34.2% (95% CI, 18.7% to 49.7%), a sensitivity of 83.3% (95% CI, 71.2% to 95.5%), a PLR of 1.27, and an NLR of 0.49. An Api m 10 sIgE level of 26.55 kU A /L provided a specificity of 95% (95% CI, 90.0% to 100%), a sensitivity of 8.3% (95% CI, 0% to 17.4%), a PLR of 2.19, and an NLR of 0.95.
ROC analysis of the percentage of Api m 10 sIgE in relation to HBV sIgE (AUC, 0.667; P 5 .004) showed the best discrimination at 47.7%, with a specificity of 93.7% (95% CI, 85.7% to 100%), a sensitivity of 33.3% (95% CI, 17.9% to 48.7%), a PLR of 5.28, and an NLR of 0.71. Specificity and sensitivity levels at different percentages of Api m 10 sIgE to HBV sIgE are displayed in Fig 3, B . When more than 50% of HBV sIgE was directed against Api m 10, the test showed a specificity of 96.2% (95% CI, 90.0% to 100%) and a sensitivity of 25% (95% CI, 10.9% to 39.1%), with a PLR of 6.58 and an NLR of 0.78. This observation suggested that patients with a predominant sensitization to Api m 10 are at a higher risk of VIT treatment failure. To address this relationship, we analyzed the ORs for different percentage of sIgE to Api m 10 in relation to sIgE to HBV. Indeed, increasing percentages of sIgE to Api m 10 (in relation to sIgE to HBV) were associated with increasing OR for treatment failure (Fig 3, C) . Notably, all subjects with sIgE to Api m 10 exceeding 60% of sIgE to HBV (n 5 8) were treatment nonresponders. No such relationship was observed for sensitization to Api m 1, Api m 2, Api m 3, or Api m 5 (see Table E1 in this article's Online Repository at www.jacionline. org). Similarly, when comparing responders and nonresponders regarding the induction of sIgG 4 to HBV (i1), Api m 1, Api m 3, and Api m 10 during VIT, no significant differences were observed (see Fig E3 in this article's Online Repository at www.jacionline.org).
Analysis of Api m 1, Api m 3, and Api m 10 in crude and therapeutic HBV preparations
The initial evidence for the absence or underrepresentation of Api m 10 and Api m 3 in therapeutic HBV preparations was obtained using recombinant IgE antibodies isolated by combinatorial technologies. 13 To provide a more solid basis for analyzing the presence of allergens in crude and therapeutic HBV preparations, specific polyclonal antisera were generated in rabbits immunized with Api m 1, Api m 3, or Api m 10 (see Fig E4 in this article's Online Repository at www.jacionline. org). On applying these polyclonal antibodies in immunoblot analysis of 2 different sources of crude HBV, we found that all sera detected the corresponding proteins at the expected size and with comparable intensity. For Api m 3 and Api m 10, bands at 55 and 50 kDa, respectively, were detected (Fig 4, A and B ). For Api m 1, 3 bands were detected at 15 to 20 kDa, representing the main glycoforms (Fig 4, C) . In addition, 5 different therapeutic HBV preparations were analyzed at identical concentrations (1 mg/mL), all of which exhibited a clear reactivity with antisera directed to Api m 1 and Api m 3, comparable to that of crude HBV (Fig 4, B therapeutic HBV preparations showed reactivity for the Api m 10-specific antiserum at a level comparable to that detected in crude venom when tested at a concentration of 0.3 mg/mL. These data corroborate the absence (or significant underrepresentation) of Api m 10 in some therapeutic HBV preparations (Fig 4, A) .
Comparison of Api m 10-specific sIgE and IgG 4 responses in patients treated with different HBV preparations
Differences in Api m 10 concentrations among therapeutic HBV preparations prompted us to compare Api m 10-specific IgE and IgG 4 responses in patients who had received VIT using HBV preparations with low or no Api m 10 (group I, n 5 59) and those who had received VIT using a HBV preparation with welldetectable Api m 10 immunoreactivity (group II, n 5 50). VIT induced a moderate but significant reduction in sIgE to Api m 10 in both treatment groups (Fig 5, A) . In contrast, significant induction of sIgG 4 was observed only in those patients treated with the HBV that contained detectable amounts of Api m 10 (group II, Fig 5, B) .
DISCUSSION
Treatment failure in HB VIT has been suggested to be associated with the complexity of venom composition and the presence of individual sensitization profiles. [5] [6] [7] [8] Additional risk factors include elevated baseline serum tryptase, concomitant mast cell disorders, 6, 18, 19 systemic allergic reactions during VIT build-up or maintenance phase, and angiotensin-converting enzyme inhibitor medication at the time of sting challenge. 6 For the present study, patient charts were analyzed for evidence of known risk factors to exclude potential confounder effects. As summarized in Table I , both patient groups were comparable with regard to age, sex distribution, antihypertensive therapy, in particular ACE inhibitor medication, percentage of double VIT, and treatment duration. When analyzing the highest degree of sting reaction before VIT, in the present study nonresponders displayed a higher percentage of severe reactions (grades III and IV) as compared with responders (33.2% vs 21.6%). However, as recently demonstrated in a larger patient cohort, the degree of sting reaction before VIT does not appear to be a relevant risk factor for treatment failure. 6 A second potential difference was the percentage of patients with elevated serum tryptase concentrations and/or mastocytosis in the skin, which was lower among nonresponders than among responders (2.8% vs 5.1%). Because both parameters have been associated with increased risk of treatment failure, we would have expected the opposite and assume that this difference is random, that is, result of the relatively small study populations and thus does not constitute a relevant confounder for the present study. A comparison of sensitization profiles to the panel of recombinant HBV allergens used in this study demonstrated an increased degree of IgE sensitization to Api m 10 among the nonresponders, while no significant differences were observed for the other allergens. The best discrimination between responders and nonresponders was calculated at Api m 10 sIgE levels of 1.82 kU A /L with a specificity of 71% and a sensitivity of 70%. To obtain a specificity of 95%, an Api m 10 sIgE level of 26.55 kU A /L was required, which resulted in a drop of sensitivity to 8.3%. In conclusion, the ROCs of Api m 10 sIgE as a single parameter, although significant (AUC, 0.687; P 5 .001), were far from optimal for identifying patients who were at risk to be not protected by HBV immunotherapy.
We speculated that the percentage of Api m 10 sIgE in relation to HBV sIgE (or to total serum IgE) may be more relevant. Indeed, the ROCs of the percentage of Api m 10 sIgE (in relation to HBV sIgE) displayed a better performance. When more than 50% of HBV sIgE was directed against Api m 10, the test showed a specificity of 96.2%, a sensitivity of 25%, and an OR of 8. IgE was analyzed (see Figs E2 and E5 in this article's Online Repository at www.jacionline.org). However, the performance characteristics were less favorable, which may be due to a smaller group size and/or the fact that for a large proportion of the patients total IgE concentrations had not been analyzed in parallel with sIgE but in different laboratories. For most patients, serum samples were also available, which were obtained before the sting challenge. Again, nonresponders displayed moderately but significantly increased levels of sIgE to Api m 10 (see Fig E6 in this article's Online Repository at www.jacionline.org) and an increased percentage of sIgE to Api m 10 in relation to HBV sIgE (i1) (see Fig E7 in this article's Online Repository at www.jacionline.org) but not as prominently as in samples that were taken before initiation of VIT. In conclusion, the best test performance was obtained when analyzing the percentage of Api m 10 sIgE in relation to HBV sIgE before initiation of VIT. These data suggested that a predominant (>50%) sensitization to Api m 10 represents a relevant risk factor for VIT treatment failure in HBV allergy.
In this context, we reinvestigated the presence of Api m 1, Api m 3, and Api m 10 in different HBV preparations using polyclonal rabbit antisera in order to corroborate findings previously obtained using recombinant human IgE antibodies. 13 Monoclonal antibodies with high specificity for one epitope only might be more susceptible for interference by loss of epitope structures by unfolding, protein fragmentation, or isoform variation and thus might exhibit a lower sensitivity. We could demonstrate the presence of Api m 1 and Api m 3 in all tested HBV preparations. In contrast and consistent with our previous report, Api m 10 was underrepresented in 3 of 5 therapeutic HBV preparations while present in both crude HBV preparations analyzed (Fig 4) .
Notably, the lack of additional bands for Api m 10 makes the presence of putative Api m 10 isoforms with significantly variant molecular mass unlikely. This finding also suggests that the absence of Api m 10 in some of the therapeutic HBV preparations is not mainly caused by protein fragmentation.
Currently we speculate that processing/purification of the crude HBV during the manufacturing process may lead to the loss of Api m 10 immunoreactivity. In this context, it is of interest that Api m 10 was detectable in nonprocessed HBV preparations (as in Pharmalgen, ALK-Abell o), whereas it was not detectable in therapeutic HBV preparations that have been processed/purified to reduce low molecular weight substances (such as Aquagen, ALK-Abell o). This step has been introduced to exclude vasoactive mediators and small bioactive peptides that have been associated with local side effects of VIT. 20, 21 Because direct loss of Api m 10 on the basis of molecular size is unlikely, other indirect mechanisms during the manufacturing process may be involved and must be addressed for each product by the respective manufacturer.
The analysis of allergen-specific IgG 4 levels before and under VIT demonstrated robust induction of sIgG 4 directed against HBV or Api m 1 but no or little against Api m 3 and Api m 10 ( Fig E3) . This difference may be due to the quantities of allergens in the HBV. Although Api m 1 represents a highly abundant allergen that constitutes up to 12% of the HBV dry weight, both Api m 3 and Api m 10 are present in much smaller quantities (1% to 2% and <1%, respectively). 15 Induction of IgG 4 to any of the allergens did not allow discrimination between responders and nonresponders ( Fig E3) . Interestingly, when patients were stratified according to the type of venom used for VIT, a low but significant induction of sIgG 4 to Api m 10 was observed only in those patients treated with the HBV that contained detectable amounts of Api m 10.
The present study has clear limitations in that it used a retrospective study design using a limited number of stored sera and corresponding clinical data from patients seen at 6 different allergy clinics. The differences observed were relatively small but consistent regardless of the way they were calculated (Api m 10 sIgE values, percentage of Api m 10 sIgE to HBV sIgE, or percentage of Api m 10 sIgE to total IgE). The ROCs and the PLRs of these parameters are clearly less impressive than those of other risk markers, such as Ara h 2 in peanut allergy. This may be related to the fact that risk markers such as Ara h 2 are used in the diagnostic setting to detect IgE sensitizations associated with increased risk of severe allergic reactions including anaphylaxis. In contrast, we have used component-resolved diagnostics to address whether certain sensitization profiles are associated with different treatment outcomes, that is, an increased risk not to benefit from VIT. In this setting, the hurdle may be even higher to detect significant and clinically useful differences because more variables may influence the outcome of the therapeutic approach.
Despite these limitations, we provide for the first time evidence that patients with a predominant sensitization to Api m 10 are at increased risk of not becoming protected by HBV immunotherapy. In addition, we demonstrate that some but not all therapeutic HBV preparations lack Api m10 and that sIgG 4 Samples with sIgE levels above the LOD at both time points were used to calculate the ratio of sIgE during/before VIT (right panel) for both groups. B, sIgG 4 to Api m 10 before VIT and under VIT (left panels). Samples with sIgG 4 levels above the LOD at both time points were used to calculate the ratio of sIgG 4 during/ before VIT (right panel) for both groups. LOD, Limit of detection.
this notion will require prospective studies in which the treatment efficacy of HBV preparations with and without Api m 10 is compared and related to initial component-resolved sensitization profiles.
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Clinical implications: HBV-allergic patients with dominant sensitization to Api m 10 are at increased risk for treatment failure in HBV immunotherapy and should benefit from treatment with Api m 10-containing preparations.
METHODS
Allergens and IgE and IgG 4 antibody measurements
Recombinant Api m 2, Api m 3, and Api m 5 were expressed as secreted full-length proteins by Spodoptera frugiperda (Sf9) insect cells as recently described.
E1-E4 Api m 10 was expressed in Escherichia coli. Experimental ImmunoCAP tests (Phadia AB, Uppsala, Sweden) containing the purified HBVallergens were prepared as described. E5 In addition, commercially available ImmunoCAPs for sIgE to HBV (i1) and Api m1 (i208) and total IgE were used. All IgE and IgG 4 antibody measurements were performed using a Phadia 250 instrument according to the manufacturer's instructions (Thermo Fischer Scientific, Uppsala, Sweden). The cutoff level for positive/negative sIgE sensitization (> _0.35 kU A /L) is indicated as dotted line (Fig E1) . sIgE levels below 0.1 kU A /L were set at 0.1 kU A /L for statistical analysis and displayed separately as less than 0.1 kU A /L in Figs 1 and 5 , A. sIgG 4 antibody measurements were performed at a serum dilution of 1:100 for HBVand Api m 1 according to the manufacturer's instructions. The LOD for sIgG 4 was calculated as 89 6 22 mg A /L as described. E6 Thus, levels below 100 mg A /L were set at 100 mg A /L for statistical analysis and displayed separately as less than 100 mg A /L in the figures. sIgG4 for Api m 3 was analyzed at a 1:20 and for Api m 10 at a 1:5 dilution and values were calculated and displayed accordingly.
Generation of antisera
Recombinantly produced allergens Api m 1, Api m 3, and Api m 10 were used for immunization of rabbits according to established protocols. Immunoreactivity and specificity of the resulting antisera were assessed by ELISA using recombinant HBV proteins (Fig E3) . Purified recombinant Api m 1, Api m 2, Api m 3, Api m 5, and Api m 10 (10 mg/mL) were coated on 384-well microtiter plates (Greiner, Frickenhausen, Germany) at 48C overnight and blocked with 40 mg/mL milk powder in PBS. Thereafter, antisera were diluted 1:5.000-20.000 with 2% milk powder in TBS and were incubated in a final volume of 50 mL for 2 hours at room temperature and applied to the corresponding wells. After washing 4 times with T-PBS and PBS, alkaline phosphatase-conjugated antirabbit IgG antibodies diluted 1:30.000 in 20 mg/mL milk powder in PBS were added for 1 hour at room temperature. Signals were detected after washing 4 times with T-PBS and PBS and subsequent addition of 50 mL of substrate solution.
Immunoblot analyses of venom and VIT preparations
Crude venoms were obtained from Latoxan (Valence, France) and Entomon (Florence, Italy). The VIT preparations we assessed included Pharmalgen (ALK-Abell o), Alyostal Venin (Stallergenes), Aquagen (ALKAbell o), Venomhal (HAL Allergy), and Venomil (Allergy Therapeutics). For immunoblot procedures, crude venom as well as the therapeutic venom preparations were dissolved to a stock concentration of 1 mg/mL. Amounts of 5 mL for detection of Api m 1, Api m 3, and Api m 10 were separated under reducing conditions by SDS-PAGE using Criterion XT (12%) Bis-Tris gels and MES buffer (Biorad, Munich, Germany) and transferred by wet blotting in Towbin buffer onto nitrocellulose membranes (Roth, Karlsruhe, Germany). The membranes were blocked with 4% milk powder in TBS buffer. Allergenspecific sera were diluted 1:5.000-50.000 with 2% milk powder in TBS and applied to the corresponding membranes. Visualization of bound IgG was then performed with goat antirabbit IgG conjugated to alkaline phosphatase (Sigma-Aldrich, Hamburg, Germany) diluted 1:20.000 in 2% milk powder in TBS and nitrotetrazolium blue chloride/x-phos (Sigma-Aldrich, Hamburg, Germany) according to the recommendations of the manufacturer.
RESULTS
Prevalence of IgE sensitization to HBV allergens in HBV-allergic patients
Prevalence of IgE sensitization to HBV allergen components among the 115 HBV-allergic patients included in the study (sIgE 
IgE reactivity to Api m 10 in relation to total IgE
Although no significant differences were observed for the percentage of sIgE to HBV, Api m 1, Api m 2, Api m 3, and Api m 5, nonresponders displayed moderately but significantly increased percentage of sIgE to Api m 10 in relation to total IgE (Fig E2) .
ROC analysis of the percentage of Api m 10 sIgE in relation to total serum IgE (AUC, 0.659; P 5 .009) showed the best discrimination between responders and nonresponders at 2.9%, with a specificity of 77.3% (95% CI, 63.7% to 91.0%) and a sensitivity of 54.5% (95% CI, 38.3% to 70.8%) with a PLR of 2.40 and an NLR of 0.58. Specificity and sensitivity levels at different percentages of Api m 10 sIgE to total IgE are displayed in Fig E5. When more than 11% of total IgE was directed against Api m 10, the test showed a specificity of 95% (95% CI, 89.6% to 100%), a sensitivity of 18.2% (95% CI, 5.6% to 30.8%), a PLR of 4.55, and an NLR of 0.85.
IgG 4 reactivity to HBV allergens before and during VIT
For the analysis of IgG 4 responses, paired samples obtained before and after at least 6 months of VIT (ie, before sting challenge) were available from 73 responders and 35 nonresponders. Before VIT, sIgG 4 to HBV and to Api m 1 was detectable in most of the samples both in responders and in nonresponders (Fig E3,  A) . In contrast, sIgG 4 to Api m 3 and Api m 10 was detectable at a much lower level and a substantial proportion of the patients' sera were below the detection limit of the assay (25 of 73 responders, 10 of 35 nonresponders). Following at least 6 months of VIT, a prominent induction of sIgG 4 was observed for the highly abundant allergen Api m 1, comparable to that observed for whole HBV (Fig E3, A and B) . In contrast, no significant induction of sIgG 4 to Api m 3 and only a minor increase in sIgG 4 to Api m 10 was observed in both responders and nonresponders (Fig E3,  A) . Patients' samples with sIgG 4 levels above the cutoff of the assay at both time points were used to calculate the ratio of sIgG 4 during/before VIT. On comparing responders and nonresponders regarding the degree of sIgG 4 induction, no significant difference was observed for any of the parameters (Fig E3, B) . 
